Showing 661-670 of 5843 results for "".
Hyperpigmentation Treatment Pearls and More
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/hyperpigmentation-treatment-pearls-and-more/20161/Corey Hartman, MD shares his approach to treating periorbital hyperpigmentation in darker skin types, including using fillers to replace volume, give lift, and replace loss of bony structures and fat pads. Dr. Hartman also discusses the benefits of Cynosure’s PicoSure device to correct hyperpigmentaWhat to do if your practice’s social accounts are inactive
https://practicaldermatology.com/topics/practice-management/what-to-do-if-your-practices-social-accounts-are-inactive/20127/Social media is the can’t miss marketing platform of 2022. However, it has been around long enough that many businesses have already tried it and given up years ago. If you are among the many dermatology practices with an old, outdated, nearly inactive Facebook or other social accounts, check out thScientifically Speaking: Effective By Design with Josh Makower, MD
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-effective-by-design-with-josh-makower-md/20106/Josh Makower, MD has been at the forefront of several medical innovations. Listen in as he describes his approach and discusses his latest product with host Joel L. Cohen, MD. The Avéli device from Revelle Aesthetics is FDA-cleared to reduce cellulite in the buttocks and thighs temporarily.DermWireTV: Dupixent for Kids; Epsolay Launch; Scleroderma Awareness; Chicago Derms Celebrate Diversity
https://practicaldermatology.com/topics/practice-management/dermwiretv-dupixent-for-kids-epsolay-launch-scleroderma-awareness-chicago-derms-celebrate-diversity/20100/Epsolay (benzoyl peroxide 5%) Cream from Galderma is now available for the topical treatment of rosacea. It was developed by Sol-Gel. Dupixent from Sanofi and Regeneron is now the only biologic medicine FDA approved for use from infancy through adulthood for the management of atopic dermatitis. JuneAre Exosomes the Next Big Thing?
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/are-exosomes-the-next-big-thing/20090/Dr. Farris, co-founder (with Dr. Ted Lain) of the Science of Skincare Summit, summarizes key points from her recent article on exosomes and their potential applications for topical skincare? Are they the next big thing? Watch to find out!Ensuring Excellent Care Across LGBTQ and Sexual Minority Patients
https://practicaldermatology.com/topics/practice-management/ensuring-excellent-care-across-lgbtq-and-sexual-minority-patients/20077/The session on LGBTQ and sexual gender minority health covered a range of topics including both clinical care as well as terminology, structures, and framework. Klint Peebles, MD talks about the importance of providing excellent dermatologic care as patients face disparities and challenges in accessThe Art of Patient Scheduling
https://practicaldermatology.com/topics/practice-management/the-art-of-patient-scheduling/23676/Is your patient scheduling system working as efficiently as possible? Put these five action items in place to ensure your practice is firing on all cylinders.Scientifically Speaking: Optimizing Results with PRP
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-optimizing-results-with-prp/20034/As increasing evidence shows the benefits of PRP for hair loss, more practices are adding it to their menu. But the results of treatment can vary depending on numerous factors. Glynis Ablon, MD and Jeffrey Rapaport, MD talk to host Joel L. Cohen, MD about their approach and share expert tips to optiDermWireTV: SPF Accuracy, Dupixent PN Data, AD Pipeline
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-spf-accuracy-dupixent-pn-data-ad-pipeline/20009/Researchers from the Environmental Working Group say that many sunscreens offer less than half their stated SPF protection against UVB. The Thriving in Aesthetics educational series featuring Sabrina Fabi, MD and Steven Dayan, MD is returning with a focus on diversity in aesthetics. As eczema awareDermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global P